Comparative effects of metformin and glibenclamide on the redox balance in type 2 diabetic patients

It is known that there a strong association between oxidative stress and insulin resistance in type 2 diabetes mellitus (T2DM). Although the role of glibenclamide treatment has been evaluated, only limited evidence about its antioxidant effects diabetic patients. Moreover, previous studies showed discrepant results regarding metformin on antioxidant/ oxidant parameters The present study aimed to evaluate versus biomarkers, represented by serum malondialdehyde (MDA), nonenzymatic, enzymatic antioxidants Forty-six patients with T2DM participated this categorized into 3 groups, Group A included 17 newly diagnosed patients, group B 15 received monotherapy (1000 mg/day) for up 1 year C 14 (5 year. Serum MDA, catalase (CAT), vitamin C, E, reduced glutathione (GSH) were measured. We found significantly lower concentrations MDA higher levels (CAT, GSH, E) metformin-treated compared counterpart. Our data confirmed more beneficial effect oxidant/antioxidant status glibenclamide, therefore, provides protection against reactive oxygen species (ROS) induced damage during diabetes.